Premature Ejaculation Treatment

Premature Ejaculation Treatment

Global Premature Ejaculation Treatment Market to Reach $3.1 Billion by 2027

Amid the COVID-19 crisis, the global market for Premature Ejaculation Treatment estimated at US$1.9 Billion in the year 2020, is projected to reach a revised size of US$3.1 Billion by 2027, growing at a CAGR of 7.4% over the analysis period 2020-2027. Selective Serotonin Reuptake Inhibitors (SSRIs), one of the segments analyzed in the report, is projected to record a 6.9% CAGR and reach US$1.3 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Tricyclic Antidepressant segment is readjusted to a revised 8.4% CAGR for the next 7-year period.

The U.S. Market is Estimated at $565.4 Million, While China is Forecast to Grow at 6.9% CAGR

The Premature Ejaculation Treatment market in the U.S. is estimated at US$565.4 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$551.3 Million by the year 2027 trailing a CAGR of 6.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.8% and 6% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 6.1% CAGR.

Topical Anesthetic Agent Segment to Record 8% CAGR

In the global Topical Anesthetic Agent segment, USA, Canada, Japan, China and Europe will drive the 8.1% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$221.3 Million in the year 2020 will reach a projected size of US$380.7 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$364.3 Million by the year 2027.

Select Competitors (Total 31 Featured) -

  • Absorption Pharmaceuticals Inc.
  • Allergan PLC
  • AstraZeneca PLC
  • Bayer AG
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Innovus Pharmaceuticals Inc.
  • Merck & Co., Inc.
  • Pfizer, Inc.
  • Teva Pharmaceutical Industries Ltd.
Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Current & Future Analysis for Premature Ejaculation Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 2: World Historic Review for Premature Ejaculation Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 3: World 15-Year Perspective for Premature Ejaculation Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
TABLE 4: World Current & Future Analysis for Selective Serotonin Reuptake Inhibitors (SSRIs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 5: World Historic Review for Selective Serotonin Reuptake Inhibitors (SSRIs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 6: World 15-Year Perspective for Selective Serotonin Reuptake Inhibitors (SSRIs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
TABLE 7: World Current & Future Analysis for Tricyclic Antidepressant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 8: World Historic Review for Tricyclic Antidepressant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 9: World 15-Year Perspective for Tricyclic Antidepressant by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
TABLE 10: World Current & Future Analysis for Topical Anesthetic Agent by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 11: World Historic Review for Topical Anesthetic Agent by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 12: World 15-Year Perspective for Topical Anesthetic Agent by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
TABLE 13: World Current & Future Analysis for Phosphodiesterase Type 5 Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 14: World Historic Review for Phosphodiesterase Type 5 Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 15: World 15-Year Perspective for Phosphodiesterase Type 5 Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
TABLE 16: World Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 17: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 18: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
TABLE 19: World Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 20: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 21: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
TABLE 22: World Current & Future Analysis for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 23: World Historic Review for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 24: World 15-Year Perspective for Topical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
III. MARKET ANALYSIS
UNITED STATES
TABLE 25: USA Current & Future Analysis for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 26: USA Historic Review for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 27: USA 15-Year Perspective for Premature Ejaculation Treatment by Drug Class - Percentage Breakdown of Value Sales for Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes for the Years 2012, 2020 & 2027
TABLE 28: USA Current & Future Analysis for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 29: USA Historic Review for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 30: USA 15-Year Perspective for Premature Ejaculation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2012, 2020 & 2027
CANADA
TABLE 31: Canada Current & Future Analysis for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 32: Canada Historic Review for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 33: Canada 15-Year Perspective for Premature Ejaculation Treatment by Drug Class - Percentage Breakdown of Value Sales for Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes for the Years 2012, 2020 & 2027
TABLE 34: Canada Current & Future Analysis for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 35: Canada Historic Review for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 36: Canada 15-Year Perspective for Premature Ejaculation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2012, 2020 & 2027
JAPAN
TABLE 37: Japan Current & Future Analysis for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 38: Japan Historic Review for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 39: Japan 15-Year Perspective for Premature Ejaculation Treatment by Drug Class - Percentage Breakdown of Value Sales for Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes for the Years 2012, 2020 & 2027
TABLE 40: Japan Current & Future Analysis for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 41: Japan Historic Review for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 42: Japan 15-Year Perspective for Premature Ejaculation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2012, 2020 & 2027
CHINA
TABLE 43: China Current & Future Analysis for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 44: China Historic Review for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 45: China 15-Year Perspective for Premature Ejaculation Treatment by Drug Class - Percentage Breakdown of Value Sales for Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes for the Years 2012, 2020 & 2027
TABLE 46: China Current & Future Analysis for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 47: China Historic Review for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 48: China 15-Year Perspective for Premature Ejaculation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2012, 2020 & 2027
EUROPE
TABLE 49: Europe Current & Future Analysis for Premature Ejaculation Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 50: Europe Historic Review for Premature Ejaculation Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 51: Europe 15-Year Perspective for Premature Ejaculation Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
TABLE 52: Europe Current & Future Analysis for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 53: Europe Historic Review for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 54: Europe 15-Year Perspective for Premature Ejaculation Treatment by Drug Class - Percentage Breakdown of Value Sales for Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes for the Years 2012, 2020 & 2027
TABLE 55: Europe Current & Future Analysis for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 56: Europe Historic Review for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 57: Europe 15-Year Perspective for Premature Ejaculation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2012, 2020 & 2027
FRANCE
TABLE 58: France Current & Future Analysis for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 59: France Historic Review for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 60: France 15-Year Perspective for Premature Ejaculation Treatment by Drug Class - Percentage Breakdown of Value Sales for Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes for the Years 2012, 2020 & 2027
TABLE 61: France Current & Future Analysis for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 62: France Historic Review for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 63: France 15-Year Perspective for Premature Ejaculation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2012, 2020 & 2027
GERMANY
TABLE 64: Germany Current & Future Analysis for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 65: Germany Historic Review for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 66: Germany 15-Year Perspective for Premature Ejaculation Treatment by Drug Class - Percentage Breakdown of Value Sales for Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes for the Years 2012, 2020 & 2027
TABLE 67: Germany Current & Future Analysis for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 68: Germany Historic Review for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 69: Germany 15-Year Perspective for Premature Ejaculation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2012, 2020 & 2027
ITALY
TABLE 70: Italy Current & Future Analysis for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 71: Italy Historic Review for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 72: Italy 15-Year Perspective for Premature Ejaculation Treatment by Drug Class - Percentage Breakdown of Value Sales for Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes for the Years 2012, 2020 & 2027
TABLE 73: Italy Current & Future Analysis for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 74: Italy Historic Review for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 75: Italy 15-Year Perspective for Premature Ejaculation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2012, 2020 & 2027
UNITED KINGDOM
TABLE 76: UK Current & Future Analysis for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 77: UK Historic Review for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 78: UK 15-Year Perspective for Premature Ejaculation Treatment by Drug Class - Percentage Breakdown of Value Sales for Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes for the Years 2012, 2020 & 2027
TABLE 79: UK Current & Future Analysis for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 80: UK Historic Review for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 81: UK 15-Year Perspective for Premature Ejaculation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2012, 2020 & 2027
REST OF EUROPE
TABLE 82: Rest of Europe Current & Future Analysis for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 83: Rest of Europe Historic Review for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 84: Rest of Europe 15-Year Perspective for Premature Ejaculation Treatment by Drug Class - Percentage Breakdown of Value Sales for Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes for the Years 2012, 2020 & 2027
TABLE 85: Rest of Europe Current & Future Analysis for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 86: Rest of Europe Historic Review for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 87: Rest of Europe 15-Year Perspective for Premature Ejaculation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2012, 2020 & 2027
ASIA-PACIFIC
TABLE 88: Asia-Pacific Current & Future Analysis for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 89: Asia-Pacific Historic Review for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 90: Asia-Pacific 15-Year Perspective for Premature Ejaculation Treatment by Drug Class - Percentage Breakdown of Value Sales for Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes for the Years 2012, 2020 & 2027
TABLE 91: Asia-Pacific Current & Future Analysis for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 92: Asia-Pacific Historic Review for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 93: Asia-Pacific 15-Year Perspective for Premature Ejaculation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2012, 2020 & 2027
REST OF WORLD
TABLE 94: Rest of World Current & Future Analysis for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 95: Rest of World Historic Review for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 96: Rest of World 15-Year Perspective for Premature Ejaculation Treatment by Drug Class - Percentage Breakdown of Value Sales for Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes for the Years 2012, 2020 & 2027
TABLE 97: Rest of World Current & Future Analysis for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 98: Rest of World Historic Review for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 99: Rest of World 15-Year Perspective for Premature Ejaculation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2012, 2020 & 2027
IV. COMPETITION
Total Companies Profiled: 31

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook